Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.41 |
| ▸ | TACR2 | P21452 | 2/20 | 0.38 |
| ▸ | CETP | P11597 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530819 | 0.96 | TACR1 (0.39) | TACR1OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL5527611 | 0.90 | CETP (0.38) | TACR1OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL5526474 | 0.90 | CETP (0.42) | CETP | |
| SCHEMBL5529929 | 0.90 | CETP (0.39) | TACR1CETP | |
| SCHEMBL5523175 | 0.89 | CETP (0.36) | TACR1OPRL1OPRM1CETP | |
| SCHEMBL5528480 | 0.88 | CETP (0.41) | CETP | |
| SCHEMBL4978903 | 0.87 | CETP (0.42) | TACR1CETP | |
| SCHEMBL4982511 | 0.87 | CETP (0.42) | TACR1CETP | |
| SCHEMBL4976719 | 0.87 | CETP (0.42) | TACR1CETP | |
| SCHEMBL5528450 | 0.87 | CETP (0.42) | TACR1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994015-B1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8383660-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383660-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383660-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | TACR1 2334/4885OPRL1 2933/4885OPRM1 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.